Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Operating Leases (2021 - 2025)

Verrica Pharmaceuticals has reported Operating Leases over the past 5 years, most recently at $583000.0 for Q4 2025.

  • Quarterly results put Operating Leases at $583000.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $583000.0 (changed 0.0% YoY), and the annual figure for FY2025 was $583000.0, changed 0.0%.
  • Operating Leases for Q4 2025 was $583000.0 at Verrica Pharmaceuticals, up from $330000.0 in the prior quarter.
  • Over the last five years, Operating Leases for VRCA hit a ceiling of $1.6 million in Q1 2021 and a floor of $330000.0 in Q3 2025.
  • Median Operating Leases over the past 5 years was $1.0 million (2023), compared with a mean of $1.0 million.
  • Peak annual rise in Operating Leases hit 0.0% in 2025, while the deepest fall reached 50.38% in 2025.
  • Verrica Pharmaceuticals' Operating Leases stood at $1.4 million in 2021, then dropped by 15.18% to $1.2 million in 2022, then fell by 25.96% to $910000.0 in 2023, then plummeted by 35.93% to $583000.0 in 2024, then changed by 0.0% to $583000.0 in 2025.
  • The last three reported values for Operating Leases were $583000.0 (Q4 2025), $330000.0 (Q3 2025), and $416000.0 (Q2 2025) per Business Quant data.